Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Syntrophic interactions driving anaerobic methane oxidation in deep-sea cold seeps revealed by DNA-SIP.

iScience·2026
Same author

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

American journal of hematology·2026
Same author

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

American journal of hematology·2026
Same author

Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.

American journal of hematology·2026
Same author

Correction: A novel immune model predicts the prognosis of mantle cell lymphoma.

Frontiers in medicine·2026
Same author

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

European journal of haematology·2026
Same journal

The Distribution of Kell Blood Group Antigens and Phenotypes (K and K) Among Saudi Blood Donors of King Abdulaziz Medical City - Western Region: A Cross-Sectional Study.

Journal of blood medicine·2026
Same journal

A Delphi Consensus by Hematologists on the Burden of Treatment on Patients with Severe Hemophilia in Mexico.

Journal of blood medicine·2026
Same journal

A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.

Journal of blood medicine·2026
Same journal

ATG Plus Post-Transplantation Cyclophosphamide Improves EBV-DNA Clearance and GVHD in Patients of Adult Chronic Active Epstein-Barr Virus Disease Undergoing Allogeneic HSCT.

Journal of blood medicine·2026
Same journal

Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine Clinical Practice in Europe.

Journal of blood medicine·2026
Same journal

Malignancy-Associated Hemophagocytic Lymphohistiocytosis: An Experience of 15 Years in Polish Pediatric Hematology Centers.

Journal of blood medicine·2026
查看所有相关文章

相关实验视频

Updated: Jun 12, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.6K

特定突变预测复发/耐火性扩散型大B细胞淋巴瘤

Jing Wang1, Lei Tian2, Weilong Zhang1

  • 1Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, People's Republic of China.

Journal of blood medicine
|September 16, 2024
PubMed
概括
此摘要是机器生成的。

像CD58这样的基因突变可能预测复发/耐药性扩散型大B细胞淋巴瘤 (DLBCL). 在进展的患者中,TP53,MEF2B和CD58突变更为常见. CD58突变仅限于复发/耐药组.

关键词:
扩散大的B细胞淋巴瘤.突变特征的突变特征是什么 突变特征复发/耐药性疾病的复发有针对性的测序.

更多相关视频

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.2K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.8K

相关实验视频

Last Updated: Jun 12, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.6K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.2K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.8K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 遗传学 是一个遗传学.

背景情况:

  • 利图西马布治疗改善了扩散性大B细胞淋巴瘤 (DLBCL) 的存活率.
  • 很大一部分DLBCL患者仍然患有复发性/耐药性疾病 (rrDLBCL).

研究的目的:

  • 研究基因突变作为 rrDLBCL.进展的预测因素.
  • 为了比较DLBCL在诊断时和 rrDLBCL病例之间的突变概况.

主要方法:

  • 针对55个基因进行了向测序.
  • 在诊断活检和rrDLBCL样本中分析了突变概况.

主要成果:

  • 在进展为rrDLBCL的患者中观察到TP53,MEF2B和CD58的突变频率升高.
  • CD58突变仅在 rrDLBCL 组中发现.
  • 在免疫化疗不响应者中,CARD11突变更频繁,而EBF1突变则针对rrDLBCL.

结论:

  • 遗传突变有助于rrDLBCL的进展.
  • CD58突变可能作为DLBCL复发/耐药性结局的预测标记.